KM
Kevin McAllister, Ph.D, MBA
Chief Scientific Officer
SOM BiotechSOM Biotech Pipeline
| Drug | Indication | Phase |
|---|
| SOM3355 | Huntington's disease | Phase 3 |
| SOM1311 | Phenylketonuria (PKU) | Preclinical |
| SOM3366 | Tourette Syndrome | Preclinical |
| SOM0226 | TTR Amyloidosis | Phase 2a PoC |